Vaccine for Omicron Variant , Could Take Months, Says Moderna CEO.
CEO of Moderna Stephane Bancel
says it could be months before a vaccine targeting the omicron variant of COVID-19 is made available, CNBC reports.
CEO of Moderna Stephane Bancel
says it could be months before a vaccine targeting the omicron variant of COVID-19 is made available, CNBC reports.
Moderna reportedly expects the
variant to be highly infectious,
but data remains inconclusive.
Mutations of the spike protein of the coronavirus have been linked to
higher transmission rates.
Mutations of the spike protein of the coronavirus have been linked to
higher transmission rates.
The World Health Organization
says the omicron variant has
experienced 30 of these mutations.
The World Health Organization
says the omicron variant has
experienced 30 of these mutations.
Experts say these mutations could possibly have a negative impact on the efficacy of the coronavirus vaccines.
Experts say these mutations could possibly have a negative impact on the efficacy of the coronavirus vaccines.
Depending on how much it dropped, we might decide on
the one hand to give a higher dose of the current vaccine .., Stephane Bancel, CEO Moderna, via CNBC.
Depending on how much it dropped, we might decide on
the one hand to give a higher dose of the current vaccine .., Stephane Bancel, CEO Moderna, via CNBC.
According to CNBC, Pfizer has started to develop its own vaccine to specifically target the omicron strain.
According to CNBC, Pfizer has started to develop its own vaccine to specifically target the omicron strain.
Pfizer CEO Albert Bourla says omicrons' impact on COVID-19 vaccines remains unclear.
The company reportedly created a DNA template of the new strain on Nov. 26.
...we would be
able to have the
vaccine in less
than 100 days, Albert Bourla, CEO Pfizer, via CNBC.
...we would be
able to have the
vaccine in less
than 100 days, Albert Bourla, CEO Pfizer, via CNBC
CEO of Moderna Stephane Bancel
says it could be months before a vaccine targeting the omicron variant of COVID-19 is made available, CNBC reports.
CEO of Moderna Stephane Bancel
says it could be months before a vaccine targeting the omicron variant of COVID-19 is made available, CNBC reports.
Moderna reportedly expects the
variant to be highly infectious,
but data remains inconclusive.
Mutations of the spike protein of the coronavirus have been linked to
higher transmission rates.
Mutations of the spike protein of the coronavirus have been linked to
higher transmission rates.
The World Health Organization
says the omicron variant has
experienced 30 of these mutations.
The World Health Organization
says the omicron variant has
experienced 30 of these mutations.
Experts say these mutations could possibly have a negative impact on the efficacy of the coronavirus vaccines.
Experts say these mutations could possibly have a negative impact on the efficacy of the coronavirus vaccines.
Depending on how much it dropped, we might decide on
the one hand to give a higher dose of the current vaccine .., Stephane Bancel, CEO Moderna, via CNBC.
Depending on how much it dropped, we might decide on
the one hand to give a higher dose of the current vaccine .., Stephane Bancel, CEO Moderna, via CNBC.
According to CNBC, Pfizer has started to develop its own vaccine to specifically target the omicron strain.
According to CNBC, Pfizer has started to develop its own vaccine to specifically target the omicron strain.
Pfizer CEO Albert Bourla says omicrons' impact on COVID-19 vaccines remains unclear.
The company reportedly created a DNA template of the new strain on Nov. 26.
...we would be
able to have the
vaccine in less
than 100 days, Albert Bourla, CEO Pfizer, via CNBC.
...we would be
able to have the
vaccine in less
than 100 days, Albert Bourla, CEO Pfizer, via CNBC
Category
🗞
News